Regeneron Pharmaceuticals, Inc. REGN obtained positive opinion for its pipeline candidate linvoseltamab from the European ...

SkylineDx’s SKY92 test with fluorescence in situ hybridisation testing led to more accurate identification of high-risk myelomas.

Patients who received cilta-cel had improvements in progression-free survival and overall survival if they had sustained a minimal residual disease-negative complete response or better for at least 1 ...